Radioimmunotherapy of prostate cancer using90Y- and 177Lu-lebeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lutetium
  • Prostatic Neoplasms
  • Radioimmunotherapy
  • Radioisotopes
  • Yttrium Radioisotopes

abstract

  • Multiple (two or three) administrations of 177Lu-J591 (30-60 mCi/m2) or 90Y-J591 (17.5 mCi/m2) over a 4- to 6-month period were tolerated by the patients with manageable thrombocytopenia. Although a single large dose may deliver optimal radiation dose to kill a larger fraction of tumor cells, fractionated therapy offers the advantage of lower myelotoxicity and prolonged tumor response. With 177Lu-J591, dose fractionation in combination with taxanes should be considered as an alternative approach to achieve optimal therapeutic efficacy in patients with prostate cancer.

publication date

  • October 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-1004-0023

PubMed ID

  • 16203821

Additional Document Info

start page

  • 7195s

end page

  • 7200s

volume

  • 11

number

  • 19 II